Abstract
Currently the major treatment choices for short bowel syndrome are parenteral nutrition and small bowel transplantation[1]. Both therapies involve great fiscal challenge and recurring complications. Recent years have witnessed the promising experimental results of pharmacological rehabilitation of remnant small bowel[2-10]. Preliminary clinical trial also indicates salutary effect of growth hormone on patients with short bowel syndrome[11,12]. However, the mechanism by which growth hormone benefits the patients remains unclear. In this animal experiment we attempted to address the possibility that administration of exogenous growth hormone (GH) after massive small bowel resection can stimulate remnant small intestinal epithelial cell proliferation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
